Body surface area for adjustment of drug dose

Drug and Therapeutics Bulletin

Volumn 48, Issue 3, 2010, Pages 33-36

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; EPIRUBICIN; FLUOROURACIL; IRINOTECAN; METHOTREXATE; PACLITAXEL;

BODY HEIGHT; BODY MASS; BODY SURFACE; BODY WEIGHT; BREAST CANCER; CANCER CHEMOTHERAPY; CHILD; DOSE CALCULATION; DRUG MONITORING; DRUG TARGETING; GENOTYPE; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; OBESITY; OVARY CANCER; PRESCRIPTION; REVIEW; STOMACH CANCER;

ADULT; ANTINEOPLASTIC AGENTS; BODY SURFACE AREA; CHILD; DRUG DOSAGE CALCULATIONS; GENOTYPE; HUMANS; KIDNEY; LIVER; OBESITY; PHARMACEUTICAL PREPARATIONS;

EID: 77749327504     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.2010.01.0002     Document Type: Review

References (41)

1. Pinkel D. The use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer Res 1958; 18: 853-6.
2. Loewert M. Concept de surface corporelle: Historique et pertinence dans l'adaptation posologique. Bulletin d'Information du medicament et de pharmacovigilance 2003; 105: 1-4.
3. Gurney H. I don't underdose my patients. . . do I? Lancet Oncol 2005; 6: 637-8.
4. Gurney H. How to calculate the dose of chemotherapy. Br J Cancer 2002; 86: 1297-302.
5. Gurney H, Shaw R. Obesity in dose calculation: a mouse or an elephant? J Clin Oncol 2007; 25: 4703-4.
6. Loos WJ et al. Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens. Clin Cancer Res 2000; 6: 2685-9.
7. Newell DR. Getting the right dose in cancer chemotherapy - time to stop using surface area? Br J Cancer 2002; 86: 1207-8.
8. Mathijssen RH et al. Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference? Oncologist 2007; 12: 913-23.
9. The patient, the drug and the kidney. DTB 2006; 44: 89-95.
10. Fabre EE et al. Interest and limits of glomerular filtration rate (GFR) estimation with formulae using creatinine or cystatin C in the malnourished elderly population. Arch Gerontol Geriatr 2009; June 22 epub ahead of print; DOI:10.1016/j.archger.2009.05.010.
11. Hempel G, Boos J. Flat-fixed dosing versus body surface area based dosing of anticancer drugs: there is a difference. Oncologist 2007; 12: 924-6.
12. Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996; 14: 2590-611.
13. Lack JA, Stuart-Taylor ME. Calculation of drug dosage and body surface area of children. Br J Anaesth 1997; 78: 601-5.
14. Sawyer M, Ratain MJ. Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs 2001; 19: 171-7.
15. Lee J-Y, Choi J-W. Validity and reliability of an alginate method to measure body surface area. J Physiol Anthropol 2006; 25: 247-55.
16. Joint Formulary Committee. British National Formulary. Edition 58. London: BMJ Group and RPS Publishing, September 2009.
17. Sharkey I et al. Body surface area estimation in children using weight alone: application in paediatric oncology. Br J Cancer 2001; 85: 23-8.
18. Gehan EA, George SL. Estimation of human body surface area from height and weight. Cancer Chemother Rep 1970; 54: 225-35.
19. Haycock GB et al. Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults. J Pediatr 1978; 93: 62-6.
20. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med 1987; 31: 1098.
21. Verbraecken J et al. Body surface area in normal-weight, overweight, and obese adults. A comparison study. Metabolism 2006; 55: 515-24.
22. Kuono T et al. Standardization of the body surface area (BSA) formula to calculate the dose of anticancer agents in Japan. Jpn J Clin Oncol 2003; 33: 309-13.
23. Delanaye P et al. Indexing glomerular filtration rate for body surface area in obese patients is misleading: concept and example. Nephrol Dial Transplant 2005; 20: 2024-8.
24. van der Sijs H, Guchelaar HJ. Formulas for calculating body surface area. Ann Pharmacother 2002; 36: 345-6.
25. Ratain MJ. Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? J Clin Oncol 1998; 16: 2297-8.
26. Egorin MJ. Horseshoes, hand grenades, and body-surface area-based dosing: aiming for a target. J Clin Oncol 2003; 21: 182-3.
27. Felici A et al. Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Eur J Cancer 2002; 38: 1677-84.
28. Aciclovir 25mg/ml sterile concentrate. Summary of product characteristics, UK. Hospira UK Limited, February 2008.
29. Faber J et al. Prednisone dosing per body weight or body surface area in children with nephrotic syndrome - is it equivalent? Pediatric Nephrol 2009; 24: 1027-31.
30. Taxotere 20mg and 80mg concentrate and solvent for infusion. Summary of product characteristics, EU. Aventis Pharma S.A., June 2002.
31. de Jong FA et al. Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability. Clin Cancer Res 2004; 10: 4068-71.
32. Sparreboom A et al. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol 2007; 25: 4707-13.
33. Hunter RJ et al. Dosing chemotherapy in obese patients: actual versus assigned body surface area (BSA). Cancer Treat Rev 2009; 35: 69-78.
34. Greenman CG et al. Breast cancer adjuvant chemotherapy dosing in obese patients: dissemination of information from clinical trials to clinical practice. Cancer 2008; 112: 2159-65.
35. Lyman GH. Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Canc Netw 2009; 7: 99-109.
36. Devaney A et al. How the reclassification of kidney disease impacts on dosing adjustments. Pharm J 2006; 277: 403-4.
37. Carboplatin 10 mg/ml intravenous infusion. Summary of product characteristics, UK. Hospira UK Limited, May 2009.
38. Gurney HP et al. Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation. J Clin Oncol 1998; 16: 2299-304.
39. Epirubicin hydrochloride 2mg/ml injection. Summary of product characteristics, UK. Hospira UK Limited, January 2008.
40. Alnaim L. Therapeutic drug monitoring of cancer chemotherapy. J Oncol Pharm Pract 2007; 13: 207-21.
41. TPMT testing before azathioprine therapy? DTB 2009; 47: 9-12.